Screener
Nektar Therapeutics NKTR Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | (10,861) | (10,460) |
| Non-cash interest expense on liabilities related to the sales of future royalties | 7,942 | 4,974 |
| Loss from equity method investment | 1,750 | 4,461 |
| Stock-based compensation | 3,355 | 3,898 |
| Depreciation and amortization | 151 | 426 |
| Amortization of premiums (discounts), net | (1,663) | (1,324) |
| Changes in operating assets and liabilities: | ||
| Operating leases, net | (2,409) | (1,813) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's business segments — allocated share based compensation expense?
- Nektar Therapeutics (NKTR) reported business segments — allocated share based compensation expense of $3.36M in Q1 2026.
- How has Nektar Therapeutics's business segments — allocated share based compensation expense changed year-over-year?
- Nektar Therapeutics's business segments — allocated share based compensation expense decreased by 13.9% year-over-year, from $3.9M to $3.36M.
- What is the long-term trend for Nektar Therapeutics's business segments — allocated share based compensation expense?
- Over 2 years (2023 to 2025), Nektar Therapeutics's business segments — allocated share based compensation expense has grown at a -35.3% compound annual growth rate (CAGR), from $30.21M to $12.65M.
- What does business segments — allocated share based compensation expense mean?
- Reflects the portion of total share-based compensation expense attributed to the specific business segment based on employee participation. This metric captures the non-cash cost of equity-based incentives granted to personnel within this segment. It is essential for understanding the true cost of human capital and alignment of incentives within the segment's operations.
Ask your AI about Nektar Therapeutics's business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude